ReviewPharmacology & therapeutics2022
Progressive massive fibrosis: An overview of the recent literature.
Review in Pharmacology & therapeutics, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 38 citations in OpenAlex.
- Genetic Susceptibility to Impaired Lung Function in Underground Coal Miners from Kazakhstan.Genes · 2026Article
- Diagnostic value of serum biomarkers for identifying computed tomography abnormalities in male miners.Scientific reports · 2026Article
- Alveolar-Basal Intermediates Drive Pulmonary Fibrosis via Coordination of a Pro-Fibrotic Signaling Niche in Silicosis.bioRxiv : the preprint server for biology · 2026Article
- Bilateral giant progressive massive fibrosis mimicking lung cancer in a rubber factory worker: A rare presentation.Respiratory medicine case reports · 2026Article
- Diagnostic complexity and potentially avoidable invasive procedures before the recognition of pneumoconiosis.Frontiers in medicine · 2026Article
- Effects of dust exposure on IGF1 and autophagy related to coal workers' pneumoconiosis.Frontiers in public health · 2026Article
- Variable Manifestations of Progressive Massive Fibrosis on Chest CT: A Pictorial Essay.Journal of the Korean Society of Radiology · 2025Review
- An Integrated Strategy for Preventing and Rehabilitating Dust-Induced Occupational Bronchopulmonary Diseases: A Scoping Review.Advances in respiratory medicine · 2025Article
- PGC-1 alpha regulates mitochondrial biogenesis to promote silica-induced pulmonary fibrosis.Toxicology research · 2025Article
- Potential Health Impacts, Treatments, and Countermeasures of Martian Dust on Future Human Space Exploration.GeoHealth · 2025Review
- Integrating CT radiomics and clinical data with machine learning to predict fibrosis progression in coalworker pneumoconiosis.Frontiers in medicine · 2025Article
- Review
- Silicotuberculosis: a critical narrative review.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- Proposed Etiotypes for Chronic Obstructive Pulmonary Disease: Controversial Issues.Tuberculosis and respiratory diseases · 2024Article
- Tetrandrine slows the radiographic progression of progressive massive fibrosis in pneumoconiosis: a retrospective cohort study.BMC pulmonary medicine · 2023Article
- Workers with Suspected Diagnosis of Silicosis: A Case Study of Sarcoidosis Versus Siderosis.Healthcare (Basel, Switzerland) · 2023Article
- Nicotinamide Mononucleotide Ameliorates Silica-Induced Lung Injury through the Nrf2-Regulated Glutathione Metabolism Pathway in Mice.Nutrients · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
This review provides an overview of literature addressing progressive massive fibrosis (PMF) from September 2009 to the present. Advances are described in understanding its pathophysiology, epidemiology of the occurrence of PMF and related conditions, the impact of PMF on pulmonary function, advances in imaging of PMF, and factors affecting progression of pneumoconiosis in dust-exposed workers to PMF. Basic advances in understanding the etiology of PMF are impeded by the lack of a well-accepted animal model for human PMF. Recent studies evaluating lung tissue samples and epidemiologic investigations support an important role for the silica component of coal mine dust in causing coal workers' pneumoconiosis and PMF in contemporary coal miners in the United States and for silica in causing silicosis and PMF in artificial stone workers throughout the world. Development of PMF is associated with substantial decline in pulmonary function relative to no disease or small opacity pneumoconiosis. In recent reports, computed tomography has had greater sensitivity for detecting PMF than chest x-ray. Magnetic resonance imaging shows promise in differentiating between PMF and lung cancer. Although PMF develops in dust-exposed workers without previously identified small opacity pneumoconiosis, the presence of small opacity pneumoconiosis increases the risk for progression to PMF, as does heavier dust exposure. Recent literature does not document any effective new treatments for PMF and new therapies to prevent and treat PMF are an important need.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.